Walleye Capital LLC Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Walleye Capital LLC grew its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 30.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 560,007 shares of the company's stock after purchasing an additional 129,411 shares during the period. Walleye Capital LLC owned about 0.88% of Viridian Therapeutics worth $12,740,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Arizona State Retirement System grew its stake in shares of Viridian Therapeutics by 14.7% in the second quarter. Arizona State Retirement System now owns 13,178 shares of the company's stock worth $171,000 after purchasing an additional 1,688 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Viridian Therapeutics by 17.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company's stock worth $318,000 after acquiring an additional 2,036 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Viridian Therapeutics by 24.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company's stock valued at $156,000 after acquiring an additional 2,359 shares during the last quarter. AlphaCentric Advisors LLC increased its position in Viridian Therapeutics by 20.0% during the 3rd quarter. AlphaCentric Advisors LLC now owns 15,000 shares of the company's stock valued at $341,000 after purchasing an additional 2,500 shares during the period. Finally, DCF Advisers LLC boosted its stake in shares of Viridian Therapeutics by 22.4% in the 2nd quarter. DCF Advisers LLC now owns 17,750 shares of the company's stock valued at $231,000 after purchasing an additional 3,250 shares during the last quarter.

Insider Buying and Selling

In related news, CEO Stephen F. Mahoney purchased 21,400 shares of the business's stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average cost of $23.33 per share, with a total value of $499,262.00. Following the acquisition, the chief executive officer now owns 21,400 shares of the company's stock, valued at $499,262. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Thomas W. Beetham purchased 5,000 shares of Viridian Therapeutics stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average price of $23.41 per share, with a total value of $117,050.00. Following the transaction, the chief operating officer now owns 6,000 shares of the company's stock, valued at $140,460. This trade represents a 500.00 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 1,626,400 shares of company stock worth $30,616,312. 0.65% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

VRDN has been the topic of a number of research analyst reports. Royal Bank of Canada reaffirmed an "outperform" rating and set a $44.00 price target on shares of Viridian Therapeutics in a research report on Thursday, September 19th. BTIG Research increased their price target on Viridian Therapeutics from $56.00 to $61.00 and gave the stock a "buy" rating in a report on Thursday, September 26th. The Goldman Sachs Group lifted their price objective on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday, September 12th. Needham & Company LLC reissued a "buy" rating and set a $38.00 target price on shares of Viridian Therapeutics in a research note on Monday, November 25th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $28.00 price target (down from $31.00) on shares of Viridian Therapeutics in a research note on Monday, August 12th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $36.33.

Viridian Therapeutics Stock Down 1.5 %

VRDN traded down $0.32 during midday trading on Friday, reaching $21.55. 321,901 shares of the company were exchanged, compared to its average volume of 1,115,646. Viridian Therapeutics, Inc. has a one year low of $11.40 and a one year high of $27.20. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The company's fifty day moving average price is $22.72 and its 200 day moving average price is $17.43. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -5.00 and a beta of 1.10.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.04). Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The company had revenue of $0.09 million during the quarter, compared to analysts' expectations of $0.08 million. As a group, analysts expect that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.